Fredrik Druvefors

KI Management AB (KIM) is a venture capital investment firm located in Stockholm, on the campus of the Karolinska Institute. They are the investment advisor and manager of the Karolinska Investment Fund KB (KIF). The fund was established in 1999 by the Karolinska Institute and Alecta, a Nordic pension plan. KIM has a partnership agreement with Karolinska Innovations AB, a technology transfer entity of the Karolinska Institute. The Karolinska Institute, founded in 1810, has a medical focus and is responsible for selecting the winner of the Nobel Prize in Physiology or Medicine.

Cellectricon AB provides cell-based screening services to accelerate drug discovery. The firm develops and validates exciting central nervous system and peripheral pain assays using primary cells, accelerating the path from assay validation to compound screening. Its system is equipped with an imaging-based microplate reader to simultaneously record transient fluorescence and luminescence signals, providing real-time monitoring and readouts of cell culture response. The company was founded by Jan Owe Owesson Orwar, Daniel T. Chiu and Stig Anders Jakob Lindberg in 1999 and is headquartered in Molndal, Sweden.